GLP-1 & Incretin Research Hub
GLP-1 agonists and dual/triple incretin agonists are among the most clinically significant peptide-class medicines of the past decade — and among the most heavily marketed online. This hub explains the science and the regulatory frame, without promoting or instructing use.
Incretin receptor biology
GLP-1, GIP, glucagon receptor basics; pharmacology overview; clinical relevance; regulatory sensitivity.
GLP-1 vs GIP vs glucagon receptors
Receptor comparison, mechanistic differences, and how dual / triple agonists differ in their pharmacological profile.
Weight-loss medicine advertising caution (UK)
Why prescription-only weight-loss medicines cannot be advertised to the public in the UK, and why PeptideStacks avoids promotional framing.
Clinical-trial evidence vs online claims
How the trial evidence base actually reads, and why online claims often outrun what the trials support.
CagriSema mechanism explainer
How the amylin + GLP-1 combination works, what REDEFINE 1/2 and REIMAGINE 1-3 actually show, and why 'additive' is not the same as 'synergistic'.
Pages on PeptideStacks are reviewed when relevant new evidence becomes available. If you spot an error or have new evidence to suggest, please use our corrections policy.